Humacyte (HUMA) director Keith Anthony Jones awarded 80,000 stock options at $1.08

Rhea-AI Filing Summary

Humacyte, Inc. director Keith Anthony Jones received a grant of stock options for 80,000 shares of Common Stock. The options were awarded at an exercise price of $1.08 per share and are held directly. Following the grant, Jones holds 80,000 stock options.

According to the vesting terms, the first 25% of the option becomes exercisable on June 11, 2027. After that date, 1/48 of the option vests on the 11th of each month through June 11, 2030, with the option expiring on June 11, 2036. This is a compensation-related award rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jones Keith Anthony

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	80,000	$0.00	--

Holdings After Transaction: Stock Options (right to buy) — 80,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 80,000 options Exercise price: $1.08 per share Initial vesting date: June 11, 2027 +2 more

5 metrics

Options granted 80,000 options Stock Options (right to buy) granted to director

Exercise price $1.08 per share Exercise price for options on Humacyte Common Stock

Initial vesting date June 11, 2027 First 25% of option becomes exercisable

Final vesting date June 11, 2030 Monthly 1/48 vesting installments end

Expiration date June 11, 2036 Option expiration for the 80,000-share grant

Key Terms

Stock Options (right to buy), exercise price, vesting, expiration date

4 terms

Stock Options (right to buy) financial

"security_title: Stock Options (right to buy)"

exercise price financial

"conversion_or_exercise_price: 1.0800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-06-11T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Keith Anthony

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.08	06/11/2026		A		80,000		(1)	06/11/2036	Common Stock	80,000	$0	80,000	D

Explanation of Responses:

1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.

	/s/ Keith Anthony Jones by Dale A. Sander as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Humacyte (HUMA) report for Keith Anthony Jones?

Humacyte reported that director Keith Anthony Jones received a grant of 80,000 stock options. These options give him the right to buy Humacyte Common Stock at a fixed exercise price as part of his compensation package, not through open-market trading.

How many Humacyte (HUMA) stock options were granted to Keith Anthony Jones?

Keith Anthony Jones was granted 80,000 stock options linked to Humacyte Common Stock. All 80,000 options are shown as held following the transaction, reflecting a single compensation-related award documented in the Form 4 insider filing.

What is the exercise price of the Humacyte (HUMA) options granted to Keith Anthony Jones?

The options granted to Keith Anthony Jones have an exercise price of $1.08 per share. This means he can buy Humacyte Common Stock at $1.08 per share once the options vest and before they expire, subject to the stated vesting schedule.

When do Keith Anthony Jones’s Humacyte (HUMA) stock options begin to vest?

The first 25% of Keith Anthony Jones’s stock options become exercisable on June 11, 2027. After that initial vesting date, 1/48 of the total option grant vests monthly on the 11th of each month through June 11, 2030.

What is the vesting schedule for the 80,000 Humacyte (HUMA) stock options granted?

The vesting schedule provides that 25% of the options vest on June 11, 2027. The remaining 75% then vest in equal 1/48 monthly installments on the 11th of each month, continuing until June 11, 2030, when the grant is fully vested.

When do Keith Anthony Jones’s Humacyte (HUMA) stock options expire?

The stock options granted to Keith Anthony Jones expire on June 11, 2036. He must exercise any vested options before that expiration date if he wishes to purchase Humacyte Common Stock at the $1.08 per share exercise price.